Trial Profile

Phase 2a take home clinical trial of Lysergic Acid Diethylamide in development microdosing LSD in patients with Major Depressive Disorder

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lysergic acid diethylamide MindBio Therapeutics (Primary)
Indications Major depressive disorder
Focus Therapeutic Use

Most Recent Events

20 Jun 2024 According to MindBio Therapeutics media release, durability data from Phase 2A clinical trials in depressed patients testing MB22001. Company reported a significant and sustained antidepressant response in patient follow up one month post treatment.
12 Jun 2024 Results published in the MindBio Therapeutics media release
02 May 2024 Primary endpoint (Improvement in the Montgomery Asberg Depression Rating Scale) has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com